Company news
Viking Therapeutics, Inc. news in 2023
Viking Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023
November 12, 2023
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
October 24, 2023
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
October 22, 2023
Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023
October 17, 2023
Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
October 16, 2023
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
October 9, 2023
Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
September 5, 2023
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
July 25, 2023
Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023
July 18, 2023
Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
May 15, 2023
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
April 25, 2023
Viking Therapeutics to Report Financial Results for First Quarter 2023 on April 26, 2023
April 19, 2023
Viking Therapeutics to Present at 22nd Annual Needham Healthcare Conference
April 10, 2023
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters' Option to Purchase Additional Shares
April 2, 2023
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
March 28, 2023
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735
March 27, 2023
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
March 27, 2023
Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
February 7, 2023
Viking Therapeutics to Present at SVB Securities Global Biopharma Conference
February 6, 2023
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023
January 31, 2023
Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
January 8, 2023